Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Open Label, Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT02677948 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT02677948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02677948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Open Label, Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 1/2
Overall status
Withdrawn
Start date
October 31, 2016
Completion date
October 31, 2018
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, lymphoma, small lymphocytic